This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: March 6, 2007
Last updated: June 10, 2015
Last verified: May 2015
This exploratory study is designed to evaluate various pharmacodynamic effects of subcutaneously (SC) infused or injected pramlintide in obese, nondiabetic male and postmenopausal female (not on hormone replacement therapy) subjects. The study will also assess the safety and tolerability of pramlintide administered by SC infusion or injection.

Condition Intervention Phase
Overweight Obesity Drug: pramlintide acetate Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double‑Blind, Placebo‑Controlled, Multicenter Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To evaluate various pharmacodynamic effects (including effects on body weight, food intake, and other parameters) of subcutaneously (SC) infused or injected pramlintide in obese subjects. [ Time Frame: 73 Days ]

Secondary Outcome Measures:
  • To evaluate the safety and tolerability of SC infused or injected pramlintide in obese subjects. [ Time Frame: 73 Days ]

Enrollment: 184
Study Start Date: August 2004
Study Completion Date: May 2005
Primary Completion Date: May 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Pramlintide acetate (AC137)
Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC administration. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an osmolality modifier and 2.25 mg/mL metacresol as a preservative. The concentration of pramlintide injection to be used in this study is 0.6 mg/mL.
Drug: pramlintide acetate
Clear, colorless, sterile solution for SC administration


Ages Eligible for Study:   25 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Is <6'3" (190.5 cm) tall and weighs <300 lb (~136.3 kg)
  • Is obese with a body mass index (BMI) >=30 kg/m^2 to <=45 kg/m^2 and with a history consistent with progressive weight gain and development of obesity not secondary to drastic or traumatic initiating events (e.g., excessive weight gain due to cessation of smoking)
  • Is a nonsmoker (never smoked or has not smoked for at least 2 years)
  • Does not have a clinical diagnosis of diabetes
  • Has not had a major change in daily physical activity within 2 months prior to study start (e.g., initiation of an exercise program)
  • Usually consumes three major meals (morning, midday, and evening) each day and rarely (less than once a week) wakes up to eat during the night

Exclusion Criteria:

  • Is currently enrolled in a weight loss program or plans to enroll in a weight loss or exercise program within the next 3 months
  • Is currently treated or expected to require or undergo treatment or has been treated within 2 months before screening with medications that are excluded:

    • Over the counter antiobesity agents including herbal supplements or prescription antiobesity agents approved for the long-term (including orlistat [Xenical] and sibutramine [Meridia]) and the short-term (including phentermine [Adipex-P, Celltech, Pro-Fast SA, Pro-Fast SR, Fastin, Oby trim, Zantryl, Teramine, Phentride, Phentercot, Obephen, Oby-cap], mazindol [Sanorex and Mazanor], methamphetamine [Desoxyn], diethylpropion [Tenuate and Tenuate Dospan], phendimetrazine [Bontril, Prelu-2, Melfiat 105, Unicelles, X-Trozine, Plegine, Adipost, Obezine, Phendiet-105, PT 105] and benzphetamine [Didrex]) treatment of obesity
    • Systemic steroids by oral, intravenous, or intramuscular route or potent topical steroids that are known to result in high systemic absorption
    • Alpha- or Beta-Blockers, centrally acting sympathicolytic or sympathicomimetic agents, reserpin, guanethidine, etc.
    • Psychotropic medications (e.g., tricyclic antidepressants, monoamine oxidase [MAO] inhibitors, selective serotonin reuptake inhibitors [SSRIs], neuroleptics, lithium, and benzodiazepines)
    • Hypnotic-sedative medications or medications that may affect sleeping behavior including medications containing caffeine
    • Drugs that directly affect gastrointestinal motility, including but not limited to: metoclopramide (Reglan®) and cisapride (Propulsid®); and macrolide antibiotics such as erythromycin and newer derivatives
  • Has received any investigational drug within 3 months before study start
  • Has participated previously in a study using pramlintide
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00444561

United States, California
Research Site
Chula Vista, California, United States
Research Site
Long Beach, California, United States
Research Site
San Diego, California, United States
United States, Florida
Research Site
DeLand, Florida, United States
Research Site
Fort Lauderdale, Florida, United States
United States, Kentucky
Research Site
Lexington, Kentucky, United States
United States, Louisiana
Research Site
Baton Rouge, Louisiana, United States
Research Site
New Orleans, Louisiana, United States
United States, Montana
Research Site
Butte, Montana, United States
United States, Texas
Research Site
San Antonio, Texas, United States
Sponsors and Collaborators
Study Director: Lisa Porter, MD Amylin Pharmaceuticals, LLC.
  More Information

Responsible Party: AstraZeneca Identifier: NCT00444561     History of Changes
Other Study ID Numbers: 137-160
Study First Received: March 6, 2007
Last Updated: June 10, 2015

Keywords provided by AstraZeneca:

Additional relevant MeSH terms:
Body Weight
Signs and Symptoms
Islet Amyloid Polypeptide
Hypoglycemic Agents
Physiological Effects of Drugs
Appetite Depressants
Anti-Obesity Agents
Amylin Receptor Agonists
Molecular Mechanisms of Pharmacological Action processed this record on September 19, 2017